Return to search results.
Complete title: A Phase 3, Double-Blind Extension Study Evaluating the Efficacy and Safety of Two Different Dose Levels of Single-Agent GS-1101 (CAL-101) as Therapy for Patients with Previously Treated Chronic Lymphocytic Leukemia
|Research Study Number||2613.00|
|Principal Investigator||John Pagel, MD, PhD|
Research Study Description
Eligibility Criteria (must meet the following to participate in this study)
Other eligibility criteria may apply.
Chronic Lymphoid Leukemia (CLL); Hematologic Malignancies; Leukemia
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.